Shorter radiation held up after mastectomy with breast reconstruction
The phase 3 RT CHARM trial found a three-week course of radiation after mastectomy was no worse than the standard five-week course for reconstruction complications, at 12.3% versus 10.2%.
| Group | Value (%) |
|---|---|
| Hypofractionated | 12.3 |
| Conventional | 10.2 |
A three-week course of radiation after mastectomy was no worse than the standard five-week course for women who also had breast reconstruction, according to the phase 3 RT CHARM trial — a result that could spare many patients weeks of daily hospital visits without compromising their reconstruction or their cancer control [s1].
Shorter, more intense radiation schedules — known as hypofractionation — are already standard after lumpectomy, where they deliver the same benefit in fewer, larger daily doses. But they had been slow to catch on after mastectomy in women undergoing reconstruction, because of a specific fear: that the more concentrated dose might damage the reconstructed breast, causing wound-healing problems, scarring that hardens the implant, or outright reconstruction failure [s1]. RT CHARM was designed to fill that evidence gap directly [s1].
What the trial did
The trial enrolled women with unilateral invasive breast cancer who were planned for postmastectomy radiation and either immediate or delayed breast reconstruction [s1]. They were randomly assigned in a 1:1 ratio to the conventional schedule — 50 Gy delivered in 25 fractions over five weeks — or to a hypofractionated schedule of 42.56 Gy in 16 fractions over three weeks [s1]. Assignment was stratified by whether reconstruction was immediate or delayed and whether it used the patient's own tissue (autologous) or an implant only [s1].
RT CHARM was built as a noninferiority trial, meaning it set out to show the shorter course was not meaningfully worse rather than that it was better. The prespecified noninferiority margin was 10 percentage points, assuming a two-year complication rate of 25% with conventional radiation [s1]. The primary outcome was a composite reconstruction complication rate — pooling wound-healing problems, readmission, capsular contracture, unplanned reoperation and reconstruction failure [s1]. The study is registered as NCT03414970 [s2].
What it found
Between 2018 and 2021, 898 patients enrolled, with a median follow-up of 3.9 years; 825 were evaluable for the primary endpoint [s1]. At 24 months, reconstruction complications occurred in 12.3% of the hypofractionated group (52 of 422) and 10.2% of the conventional group (41 of 403) [s1]. The estimated difference was −2.1 percentage points, with a 95% confidence interval of −6.5 to 2.2 — comfortably inside the 10-point noninferiority margin, so the shorter course met its goal [s1].
Two further findings sharpen the picture. Complications were more common with implant-only than with autologous reconstruction regardless of which radiation schedule was used, with an odds ratio of 1.65 [s1]. And crucially for cancer control, there was no statistically significant difference in cancer coming back near the original site: the 36-month locoregional recurrence rate was 1.5% (95% CI 0.7 to 3.2) with the hypofractionated schedule and 2.2% (95% CI 1.1 to 4.3) with conventional treatment [s1]. Acute and late side-effect rates did not differ significantly between the two arms [s1].
How to read it
The design is the right one for the question. Nobody expected a shorter schedule to be more effective; the worry was harm, and a noninferiority trial is built to rule out meaningful harm within a stated margin [s1]. On the primary endpoint it did exactly that, and the recurrence and toxicity data pointed the same way [s1]. The honest limits are built into that framing: noninferiority was declared against a 10-point margin, so the trial establishes that the shorter course is not appreciably worse, not that the two are identical, and the confidence interval does extend into modestly higher complication rates [s1].
The implant-versus-autologous finding is a useful piece of counselling information in its own right, independent of radiation schedule: it suggests the type of reconstruction a patient chooses carries more weight for complications than the radiation timetable does [s1]. It is also worth noting what the trial did not test. RT CHARM enrolled women with unilateral invasive cancer planned for both radiation and reconstruction, so its findings apply to that specific group rather than to every patient facing postmastectomy radiation [s1]. And because the two schedules deliver different total doses in different-sized fractions — 50 Gy in 25 sittings versus 42.56 Gy in 16 — the equivalence shown here is between those particular regimens, not a general licence to shorten radiation however a clinic prefers [s1]. For readers following how breast cancer treatment is being refined, related coverage includes our report on atezolizumab in triple-negative breast cancer.
What to watch
Longer follow-up will firm up the recurrence and late-toxicity comparisons, which matter most over a horizon of years rather than months [s1]. If the results hold, the practical payoff is considerable: cutting a five-week daily radiation course to three weeks is a meaningful reduction in time, travel and cost for patients already navigating surgery and reconstruction [s1][s2].
This article describes research and is not medical advice. Radiation and reconstruction decisions are for patients and their treating teams.
Sources
- Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505) — Journal of Clinical Oncology , October 12, 2026
- Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence (RT CHARM) — ClinicalTrials.gov , October 12, 2026
More on
FDA approves tucatinib to maintain control of HER2-positive breast cancer
The pill joins trastuzumab and pertuzumab as maintenance after induction. In the 654-patient HER2CLIMB-05 trial it stretched median progression-free survival to 24.9 months from 16.3, a hazard ratio of 0.64.
An all-oral drug pair slowed advanced breast cancer, mostly in one mutation group
In the industry-funded evERA trial, giredestrant plus everolimus delayed progression of ER-positive breast cancer — but the clearest benefit was in ESR1-mutated tumours, and the endpoint was a surrogate, not survival.
Atezolizumab added nothing to HER2-positive breast cancer therapy in IMpassion050
Final results of the phase 3 IMpassion050 trial show adding the immunotherapy atezolizumab to standard HER2-targeted treatment did not improve event-free or disease-free survival.
FDA logs an imlunestrant efficacy approval for ER-positive advanced breast cancer
Eli Lilly's oral Inluriyo gained an FDA efficacy supplement on 18 September. In the phase 3 EMBER-3 trial, adding abemaciclib lifted median progression-free survival to 9.4 months from 5.5.